[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
    "title": "Kvartalsrapport Q2 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a459bffc7616fe23ccdb6934b4a8e0002",
    "date": "2026-07-22",
    "period": "2026-q2",
    "form_type": "interim-report",
    "report_key": "2026:q2",
    "filename": "07210802.pdf",
    "text_chars": 76479,
    "sha256": "7c96a3f10c9c5b538cb7ee4f047d7edb9ec0e39e0c83068947e292c0981fd717",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
        "chars": 76479
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ab155000ddcd14b8fb922b451c6cde179",
    "date": "2026-04-08",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "04086073.pdf",
    "text_chars": 2749,
    "sha256": "c8671a4d0e0bbf857b977456e4768af01c5bbb9e09f80e63c69414c2cb028229",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 2749
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a634d4bb5de3a51fc56afb8522e487534",
    "date": "2026-03-26",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "03250515.pdf",
    "text_chars": 445539,
    "sha256": "49d9d9919d0f1c9d567aee93c741fe03ebaaa671400b2892eb7a627a0bae2392",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 178249
      },
      {
        "number": 2,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 179453
      },
      {
        "number": 3,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-003.html",
        "chars": 87833
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a55f1a964f145fc4af177885d12b6d83b",
    "date": "2026-02-11",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "02109163.pdf",
    "text_chars": 72029,
    "sha256": "d1223c9b80e05d8e24cc6206176c82ee7c77a707cce1d8869d5739d07625970b",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 72029
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a3590db052477e7010a784d8beedc6948",
    "date": "2025-10-08",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "10080337.pdf",
    "text_chars": 2668,
    "sha256": "81d8dd5069731af167e9477ed92479d1f82820bad7be0d1cc700ce44afcd146d",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 2668
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2bd7541ee4c7707a91027cb2363ce721",
    "date": "2025-07-17",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "07160514.pdf",
    "text_chars": 74346,
    "sha256": "95329c9a7d31ef1580cad5cdec7d71cd76582fbd8615f73a353ea1ad9fe0fde6",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 74346
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a613ec82fbb278a21614a73ef93f20139",
    "date": "2025-04-03",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "04021269.pdf",
    "text_chars": 2581,
    "sha256": "9757e217aebb392fd75b36a374dc4017532db1289f8b5faac734b3a2c7b686a0",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 2581
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aa901e5d2cd9ac8b3aaa9618272fc2b8b",
    "date": "2025-03-21",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "03193018.pdf",
    "text_chars": 360363,
    "sha256": "7c540e35d6f3f4a0e40aa1e081539f9730535717e44ef61bda852af2bc5cbc9e",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 177176
      },
      {
        "number": 2,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 179660
      },
      {
        "number": 3,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-003.html",
        "chars": 3523
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae2fb4bf053952c35f5cf2df99b8852a3",
    "date": "2025-02-06",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "02052870.pdf",
    "text_chars": 71941,
    "sha256": "151f7539d9c6f657803854c8f80d46dd7214f9365db2e625dd84242a5350ee94",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 71941
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a15b7936b44769b5c49ea28b8204c68c9",
    "date": "2024-10-17",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "10163165.pdf",
    "text_chars": 68578,
    "sha256": "53111b306a1871a47c7508f7de23599732427a104cc3e3b24b94a19c575da595",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 68578
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a91de3c49fc04dfc22b6a52fd9d24b0bc",
    "date": "2024-07-18",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "07176835.pdf",
    "text_chars": 70776,
    "sha256": "0611d6c9b6d265cd14379e5db790a6d2d0c06a59f0a3049c870534620b1f89a0",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 70776
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a244337ed6b472b581999f12183b6b20d",
    "date": "2024-04-18",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "04173308.pdf",
    "text_chars": 65947,
    "sha256": "0e9ae5296cff8282e0304d048ef7bb227ddadb4471c70535a7c9245c4e27b6d0",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 65947
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2e5ffea0a02f73d653940969caf5f244",
    "date": "2024-04-02",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "04014780.pdf",
    "text_chars": 4591,
    "sha256": "58dcb731cbfae3151f20aa822b0f2491697a1ff6c3e1457b02e30c125eeef6dc",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 4591
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac2ec62f7431c2add29251f632a572de0",
    "date": "2024-03-21",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "03198022.pdf",
    "text_chars": 353279,
    "sha256": "fb8b5f620dbe4273367fc8d969b17cd231b9aafa532176edf7ac960661aa5224",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 175721
      },
      {
        "number": 2,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 177556
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae94c624f4ac4255a0a806a1066b6beb7",
    "date": "2023-10-26",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "10251421.pdf",
    "text_chars": 63461,
    "sha256": "5514d6c77dab35b5fc1d89254e52c8d4288ab1a10a00751190267751d9cb030a",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 63461
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aa98541d31c2230c51e17bbf59b28fc40",
    "date": "2023-07-20",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "07195864.pdf",
    "text_chars": 62020,
    "sha256": "13def23a6a8ea0e34bade469c95719c3eaffdd413e934a5fd2e1a68b31488247",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 62020
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a5e83ef50796120f143d6d264e5861db7",
    "date": "2023-04-20",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "04192209.pdf",
    "text_chars": 55710,
    "sha256": "e6869fb0bb1decdc5f18bf1677e7aa3161bacca0ecabb155b1775fb08aad5f45",
    "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 55710
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/hansa-biopharma",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 14694,
    "sha256": "efcb5106d4da6aeeace43bef026a35bf8633f3814ca5d1589cde55c3b5551106",
    "url": "/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 14694
      }
    ]
  }
]